This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01446/identifier/chemspider/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01446/identifier/chebi/
n15http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB01446/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01446/identifier/bindingdb/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01446/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01446/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01446/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB01446
rdf:type
n3:Drug
n3:description
A stimulant and psychoactive drug which produces effects similar to 3,4-methylenedioxy-N-methylamphetamine (MDMA), despite being structurally dissimilar. It was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, alpha-methyltryptamine became regulated as a Schedule I controlled substance in the United states.
n3:group
experimental illicit
owl:sameAs
n6:DB01446 n15:DB01446
dcterms:title
Alpha-methyltryptamine
adms:identifier
n9:8930 n10:DB01446 n11:50014210 n12:9287 n13:46507024 n14:Alpha-methyltryptamine n16:59020
n3:synonym
αMT IT-403 164E 3-IT IT-290 Indopan AMT
n3:toxicity
Long lasting serotonin neuro-toxicity at high doses is potentially possible, and is seen with a close analogue of alpha-methyltryptmaine: alpha-ethyltryptamine.
n3:IUPAC-Name
n4:271B4BF6-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4BFC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4BFB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4BF8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4BF9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4BFA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4BF4-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4BF5-363D-11E5-9242-09173F13E4C5 n4:271B4BF2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4BF3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4C02-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4C03-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4BFD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4BFE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4C00-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4BFF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4C01-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
299-26-3
n3:category
n3:Bioavailability
n4:271B4C08-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4C0A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4C0B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4C0C-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4C07-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4C06-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4C09-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4BF7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4C04-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4C05-363D-11E5-9242-09173F13E4C5